Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Marcos de Lima, MD, Betul Oran, MDMS, Richard E. Champlin, MD, Esperanza B. Papadopoulos, MD, Sergio A. Giralt, MD, Bart L. Scott, MD, Basem M. William, MD, Joel Hetzer, PhD, Becky Hubbell, PharmD, Barry S. Skikne, MD, Charles Craddock

Blood (2017) 130 (Supplement 1): 4512.

https://doi.org/10.1182/blood.V130.Suppl_1.4512.4512

Published: 2017

Journal Articles

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Steven D. Gore, MD, Bart L. Scott, MD, Christopher R. Cogle, MD, Thomas Boyd, MD, Paul Conkling, Joel Hetzer, PhD, Qian Dong, MS, Keshava Kumar, PhD, Stacey M. Ukrainskyj, BSN, Barry S. Skikne, MD

Blood (2016) 128 (22): 905.

https://doi.org/10.1182/blood.V128.22.905.905

Published: 2016

Journal Articles

CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)

Michael R. Savona, MD, Steven D. Gore, MD, Kathryn S. Kolibaba, Stacey M. Ukrainskyj, BSN, Keshava Kumar, PhD, Qian Dong, MS, Joel Hetzer, PhD, Barry Skikne, MD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 452.

https://doi.org/10.1182/blood.V126.23.452.452

Published: 2015

Journal Articles

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Basem M. William, MD, Marcos de Lima, MD, Betul Oran, MD, Richard Champlin, MD, Esperanza B Papadopoulos, MD, Sergio Giralt, MD, Bart L. Scott, MD, Joel Hetzer, PhD, Xiwei Wang, PhD, Eric Laille, MS, Barry S. Skikne, MD, Charles Craddock, MDPhD

Blood (2014) 124 (21): 990.

https://doi.org/10.1182/blood.V124.21.990.990

Published: 2014

Journal Articles

Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS)

Guillermo Garcia -Manero, MD, Michael Savona, MD, Steven D. Gore, MD, Christopher R. Cogle, MD, Paul Conkling, MD, CL Beach, PharmD, Joel Hetzer, PhD, Qian Dong, MS, Barry S. Skikne, MD

Blood (2013) 122 (21): 1554.

https://doi.org/10.1182/blood.V122.21.1554.1554

Published: 2013

Journal Articles

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

John F Seymour, MB, BS, PhD, FRACP, John M. Bennett, MD, Alan F List, MD, Ghulam J. Mufti, MD, Steven D. Gore, MD, Pierre Fenaux, MD, PhD, Valeria Santini, MD, Joel Hetzer, PhD, Stephen Songer, PharmD, Barry S. Skikne, MD, C.L. Beach, PharmD

Blood (2012) 120 (21): 3808.

https://doi.org/10.1182/blood.V120.21.3808.3808

Published: 2012

Journal Articles

Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Suman Kambhampati, MD, Bart L Scott, MD, MS, Ayalew Tefferi, MD, Christopher R Cogle, MD, William Edenfield, MD, Joel Hetzer, PhD, Keshava Kumar, PhD, Barry S. Skikne, MD

Blood (2012) 120 (21): 424.

https://doi.org/10.1182/blood.V120.21.424.424

Published: 2012

NARROW

Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS)

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS)

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only